Illumina (NASDAQ:ILMN) just teamed up with NVIDIA (NASDAQ:NVDA) to shake up the genomics and drug discovery gameand investors, take note. This partnership fuses Illumina's top-notch sequencing tech with NVIDIA's AI muscle to make genomic data analysis faster, smarter, and more accessible. The cherry on top? Illumina's DRAGEN analysis software will now leverage NVIDIA's accelerated computing, meaning global pharma players can dig deeper into genomic insights and uncover game-changing drug targets.
But it doesn't stop there. At the J.P. Morgan Healthcare Conference, NVIDIA unveiled a lineup of new partnerships with heavyweights like IQVIA (NYSE:IQV) and Mayo Clinic, doubling down on AI's role in the $10 trillion healthcare industry. Mayo Clinic, for instance, is diving into AI-powered pathology, while Arc Institute is scaling AI models across DNA, RNA, and proteins. These moves put NVIDIA at the epicenter of a healthcare AI revolution that's tackling everything from drug discovery to personalized medicine.
Here's the twist: NVIDIA's big ambitions are hitting some turbulence. New U.S. export rules on AI chips are drawing sharp criticism from the company, with execs warning they could hurt innovation and America's global AI edge. Despite this, NVIDIA's relentless focus on reshaping healthcare through AI keeps it firmly in the driver's seat. For investors, this fusion of genomics and AI spells one thing: opportunity.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.